331 related articles for article (PubMed ID: 35945627)
1. The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade.
Geisen UM; Rose R; Neumann F; Ciripoi M; Vullriede L; Reid HM; Berner DK; Bertoglio F; Hoff P; Hust M; Longardt AC; Lorentz T; Martini GR; Saggau C; Schirmer JH; Schubert M; Sümbül M; Tran F; Voß M; Zeuner R; Morrison PJ; Bacher P; Fickenscher H; Gerdes S; Peipp M; Schreiber S; Krumbholz A; Hoyer BF
J Med Virol; 2022 Dec; 94(12):5780-5789. PubMed ID: 35945627
[TBL] [Abstract][Full Text] [Related]
2. Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors.
Lu BN; Zhu KL; Cui XM; Yao L; Wang XJ; Wang GL; Duan LJ; Qian A; Ma MJ
Clin Immunol; 2022 Nov; 244():109103. PubMed ID: 36049602
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - implications for the omicron variant.
Peled Y; Afek A; Kreiss Y; Rahav G; Nemet I; Kliker L; Indenbaum V; Ram E; Lavee J; Segev A; Matezki S; Sternik L; Raanani E; Lustig Y; Patel JK; Mandelboim M
J Heart Lung Transplant; 2022 Oct; 41(10):1417-1425. PubMed ID: 35710484
[TBL] [Abstract][Full Text] [Related]
4. Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant.
Seaman MS; Siedner MJ; Boucau J; Lavine CL; Ghantous F; Liew MY; Mathews JI; Singh A; Marino C; Regan J; Uddin R; Choudhary MC; Flynn JP; Chen G; Stuckwisch AM; Lipiner T; Kittilson A; Melberg M; Gilbert RF; Reynolds Z; Iyer SL; Chamberlin GC; Vyas TD; Vyas JM; Goldberg MB; Luban J; Li JZ; Barczak AK; Lemieux JE
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36214224
[TBL] [Abstract][Full Text] [Related]
5. The Impact of COVID-19 and Vaccine on the Human Nervous System.
Chen F; Cao P; Liu H; Cai D
Neuroendocrinology; 2022; 112(11):1046-1057. PubMed ID: 35316815
[TBL] [Abstract][Full Text] [Related]
6. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
7. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P
Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
9. Early humoral and cellular responses after bivalent SARS-CoV-2 mRNA-1273.214 vaccination in long-term care and retirement home residents in Ontario, Canada: An observational cohort study.
Breznik JA; Rahim A; Bhakta H; Clare R; Zhang A; Ang J; Stacey HD; Liu LM; Kennedy A; Bilaver L; Hagerman M; Kajaks T; Bramson JL; Nazy I; Miller MS; Costa AP; Bowdish DME;
J Med Virol; 2023 Oct; 95(10):e29170. PubMed ID: 37822054
[TBL] [Abstract][Full Text] [Related]
10. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P
Front Immunol; 2022; 13():909910. PubMed ID: 35784321
[TBL] [Abstract][Full Text] [Related]
11. Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases.
Liu Y; Lu J; Zhan H; Yuan W; Li X; Kang H; Li H; Chen Y; Cheng L; Sun X; Zheng H; Wang W; Dai E; Li Y
Virol Sin; 2023 Oct; 38(5):723-734. PubMed ID: 37487943
[TBL] [Abstract][Full Text] [Related]
12. High Uptake and Series Completion of COVID-19 Vaccine at Community-Based Vaccination for Latinos With Limited English Proficiency.
Bigelow BF; Saxton RE; Martínez DA; Flores-Miller A; Shin JM; Parent C; Williams S; Phillips KH; Yang C; Page KR
J Public Health Manag Pract; 2022 Nov-Dec 01; 28(6):E789-E794. PubMed ID: 36074797
[TBL] [Abstract][Full Text] [Related]
13. Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders.
Sauerwein KMT; Geier CB; Stemberger RF; Rossmanith R; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
J Allergy Clin Immunol; 2023 Apr; 151(4):922-925. PubMed ID: 36463978
[TBL] [Abstract][Full Text] [Related]
14. Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies.
Geisen UM; Sümbül M; Tran F; Berner DK; Reid HM; Vullriede L; Ciripoi M; Longardt AC; Hoff P; Morrison PJ; Schneider VE; Zeuner R; Schirmer JH; Steinbach A; Nikolaus S; Gerdes S; Schreiber S; Bacher P; Hoyer BF
RMD Open; 2021 Dec; 7(3):. PubMed ID: 34880128
[TBL] [Abstract][Full Text] [Related]
15. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
16. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
17. Diverse effects on vaccine-specific serum IgG titres and memory B cells upon methotrexate and anti-TNF-α therapy in children with rheumatic diseases: A cross-sectional study.
Ingelman-Sundberg HM; Laestadius Å; Chrapkowska C; Mördrup K; Magnusson B; Sundberg E; Nilsson A
Vaccine; 2016 Mar; 34(10):1304-11. PubMed ID: 26827664
[TBL] [Abstract][Full Text] [Related]
18. One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort.
Loubet P; Wittkop L; Ninove L; Chalouni M; Barrou B; Blay JY; Hourmant M; Thouvenot E; Laville M; Laviolle B; Lelievre JD; Morel J; Quoc SN; Spano JP; Terrier B; Thiebaut A; Viallard JF; Vrtovsnik F; Circosta S; Esterle L; Levier A; Vanhems P; Tartour E; Parfait B; de Lamballerie X; Launay O;
Clin Microbiol Infect; 2023 Mar; 29(3):388.e1-388.e8. PubMed ID: 36252789
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients.
Overheu O; Lendowski S; Quast DR; Kühn D; Vidal Blanco E; Kraeft AL; Steinmann E; Kourti E; Lugnier C; Steinmann J; Reinacher-Schick A; Pfaender S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10633-10644. PubMed ID: 37300723
[TBL] [Abstract][Full Text] [Related]
20. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
